抗VEGF药物治疗继发于病理性近视的脉络膜新生血管的新进展

继发于病理性近视的脉络膜新生血管(choroidal neovascularization，CNV)是造成不可逆中心视力丧失的常见原因，发病率高且严重影响患者的生活质量。传统治疗模式包括热激光光凝术、经瞳孔热疗法以及使用维替泊芬的光动力学疗法。但是，这些治疗方法的长期结果不容乐观。而玻璃体内注射抗VEGF的治疗能够比传统方式更有效地提高视力，减少中央视网膜厚度。因此，这些抗VEGF药物有可能成为治疗继发于病理性近视CNV的一线药物。本综述通过讨论近视CNV的发病机制，抗VEGF药物的分子结构和作用机制，比较抗VEGF药物对继发于病理性近视CNV的治疗功效和安全性。

Recent advance on anti-VEGF treatment of choroidal neovascularization secondary to pathological myopia

The choroidal neovascularization(CNV)secondary to pathological myopia is a common cause of irreversible central vision loss, with high incidence and serious impact on the quality of life of the patients. The traditional therapeutic modalities for CNV secondary to pathologic myopia include thermal laser photocoagulation, transpupillary thermotherapy, and photodynamic therapy with verteporfin. However, the long-term outcome of these treatments are disappointing. Recently, the intravitreal injection of anti- vascular endothelial growth factor(VEGF)treatment can improve the visual acuity and reduce the central retina thickness more effectively than the traditional method. Therefore, these anti-VEGF agents may become first-line drugs for the treatment of CNV secondary to pathological myopia. This review is aim to discuss the pathogenesis of myopic CNV, the molecular structure and mechanism of anti-VEGF drugs, and compare the therapeutic efficacy and safety of anti-VEGF drugs to CNV secondary to pathologic myopia.